Galectin Therapeutics Inc. (GALT)

[biotech2010]

The company has been in limbo for quite awhile without anything to report.

Today's announcement of the FX trial enrollment being completed, while routine, shows they are on track to complete this trial and yesterday's mention of upcoming interim psoriasis results again shows they are hitting their marks on a consistent basis.

The stock is way undervalued if they have a potentially valuable drug (mostly due to the Feuerstein bear bs and resultant worthless lawsuits) but there really isn't anything that will change the direction other than positive trial results-all shareholders can do is hope all of the pre-clinical information and the Phase 1 are predictive of the Phase 2 results (I do or wouldn't have added many shares over the past year).